Key facts
- This page summarizes Andrew A. Dahl's Form 4 filing for Zivo Bioscience, Inc. (ZIVO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 Oct 2021, 19:07.
Andrew A. Dahl - 21 Oct 2021 Form 4 Insider Report for Zivo Bioscience, Inc. (ZIVO)
- Reporting relationship
- President / CEO, Director
- Issuer ticker
- ZIVO
- Reported as of
- 21 Oct 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Andrew A. Dahl
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Andrew A. Dahl filed Form 4 for Zivo Bioscience, Inc. (ZIVO) on 25 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZIVO
transaction
Derivative
Nonstatutory Stock Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +376,000
- Change %
- Price
- $0.000000
- Shares after
- 376,000
- Date
- 21 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 376,000
- Exercise price
- $5.50
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant.